



April 29, 2022

**BSE Limited**

Department of Corporate Services,  
P. J. Towers,  
Dalal Street,  
**MUMBAI - 400 001.**

✓ **National Stock Exchange of India Limited**

Exchange Plaza,  
Bandra Kurla Complex,  
Bandra (East),  
**Mumbai - 400 051.**

*Dear Sir/Madam,*

**Sub: Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Enclosed is a Press Release as regards, Lupin Diagnostics having launched the Reference Laboratory in Guwahati, Assam.

This may kindly be considered as a disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The above is for your information and dissemination.

Thanking you,

**For LUPIN LIMITED**

**R. V. SATAM  
COMPANY SECRETARY  
(ACS - 11973)**



**Encl: a/a.**

LUPIN LIMITED

Registered Office: 3<sup>rd</sup> Floor, Kalpataru Inspire, Off W. E. Highway, Santacruz (East), Mumbai - 400 055 India. Tel : (91-22) 6640 2323.

Corporate Identity Number: L24100MH1983PLC029442

[www.lupin.com](http://www.lupin.com)

## Lupin Launches its Reference Laboratory in Guwahati, Assam

*Expanding Diagnostics Business footprint in North East India*

**Guwahati, India, April 29, 2022:** Global pharma major Lupin Limited (Lupin) announced today that Lupin Diagnostics has launched its Reference Laboratory in Guwahati in North East India. The expansion is in line with Lupin Diagnostics' strategy to expand its presence across India and increase access to quality testing.

The Reference Laboratory in Guwahati has capabilities to conduct a broad spectrum of routine and specialized tests in the fields of molecular diagnostics, cytogenetics, flow cytometry, histopathology, cytology, microbiology, serology, hematology, immunology and routine biochemistry.

"Doctors and patients rely on diagnostic test results to make informed decisions – accurate diagnosis is the first step towards managing diseases and identifying appropriate line of treatment," said **Ravindra Kumar, Vice President and Head – Lupin Diagnostics.**

"We believe that access to accurate and affordable diagnostic services is a necessity across the country. Hence we are pleased to announce our expansion in the North-Eastern regions of India," **he added.**

After Assam and West Bengal, Lupin Diagnostics is also setting up laboratories in Bihar, Jharkhand and Orissa to comprehensively cater to the Eastern region of India. These processing labs will be located in Patna (Bihar), Ranchi (Jharkhand) and Bhubaneswar (Orissa), in addition to multiple cities across West Bengal. These labs will be connected to Lupin's franchise collection centers, LupiMitra. At present, Lupin Diagnostics has more than 250 LupiMitra enrolled across the country.

Lupin Diagnostics offers a comprehensive range of diagnostics services to doctors, patients and consumers. Some of its key consumer-centric features are GPS-enabled, temperature-controlled sample movement, smart reports, NABL accreditation of each laboratory, trend report analysis, and live home collection booking and tracking. The company started its journey by establishing a state-of-the-art 45,000 square foot National Reference Laboratory in Navi Mumbai with world-class equipment, experienced doctors assisted by trained technologists and stringent quality control protocols.

### **About Lupin**

Lupin is an innovation-led transnational pharmaceutical company headquartered in Mumbai, India. The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa and across Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.



BSE: 500257

NSE: LUPIN

REUTERS: LUPIN.BO

BLOOMBERG: LPCIN

The Company enjoys leadership position in the cardiovascular, anti-diabetic, and respiratory segments and has significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS) and women's health areas. Lupin is the third largest pharmaceutical company in the U.S. by prescriptions. The company invested 9.6% of its revenue on research and development in FY21.

Lupin has 15 manufacturing sites, 7 research centres, more than 20,000 professionals working globally, and has been consistently recognized as a 'Great Place to Work' in the Biotechnology & Pharmaceuticals sector.

Please visit [www.lupin.com](http://www.lupin.com) for more information.

Follow us on Twitter: <https://twitter.com/LupinGlobal> | LinkedIn: <https://www.linkedin.com/company/lupin>

Facebook: <http://www.facebook.com/LupinWorld/>

Please visit <https://www.lupindiagnosics.com/> for best-in-class diagnostic experiences with Lupin Diagnostics.

**For further information or queries please contact –**

**Shweta Munjal**

Vice President & Global Head – Corporate Communications

Email: [shwetamunjal@lupin.com](mailto:shwetamunjal@lupin.com)